Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Andrew S. Fein downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Buy to Neutral and lowers...
Citigroup analyst Yigal Nochomovitz downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Buy to Neutral and lowers the price ...
Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but...
BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $48 to...
Guggenheim analyst Seamus Fernandez downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Buy to Neutral.
